Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability: an open-label, single-arm, singlecenter, pilot study

Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability: an open-label, single-arm, singlecenter, pilot study - Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032308

Enrollment

Registered

2018-04-18

Start date

2018-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic encephalopathy

Interventions

Subjects are administered 400mg of rifaximine once orally after meal three times a day. They take medicine after registration for 28 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who had a diagnosis of cirrhosis by pathology or diagnostic imaging. The patient have minimal hepatic encephalopathy or hepatic encephalopathy. The patient that treatment does not have the change for three months.

Exclusion criteria

Exclusion criteria: The patient with the change of the medicine for the hepatic encephalopathy within agreement acquisition three months ago. The patient who corresponds to a taboo listed in the attached document of rifaximine.

Design outcomes

Primary

Measure	Time frame
The amount of change from a baseline of blood endotoxin activity in four weeks.	—

Countries

Japan

Contacts

Public ContactHonda Yasushi

Yokohama City University Graduate School of Medicine Gastroenterology and Hepatology

y-honda@umin.ac.jp045-787-2640

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026